Fulgent Genetics Valuation
| FLGT Stock | USD 20.13 0.04 0.20% |
At this time, the firm appears to be undervalued. Fulgent Genetics shows a prevailing Real Value of $24.59 per share. The current price of the firm is $20.13. Our model computes the value of Fulgent Genetics from reviewing the firm fundamentals such as Profit Margin of (0.58) %, current valuation of 203.76 M, and Shares Outstanding of 29.9 M as well as analyzing its technical indicators and probability of bankruptcy. In general, most investors advise acquiring undervalued instruments and selling overvalued instruments since, at some point, asset prices and their ongoing real values will submerge. Key fundamental drivers impacting Fulgent Genetics' valuation include:
Price Book 0.5477 | Enterprise Value 203.8 M | Enterprise Value Ebitda (4.34) | Price Sales 2.1484 | Forward PE 7.9365 |
Undervalued
Today
Please note that Fulgent Genetics' price fluctuation is very steady at this time. Calculation of the real value of Fulgent Genetics is based on 3 months time horizon. Increasing Fulgent Genetics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Fulgent Genetics is useful when determining the fair value of the Fulgent stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Fulgent Genetics. Since Fulgent Genetics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Fulgent Stock. However, Fulgent Genetics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 20.13 | Real 24.59 | Target 36.5 | Hype 20.33 |
The real value of Fulgent Stock, also known as its intrinsic value, is the underlying worth of Fulgent Genetics Company, which is reflected in its stock price. It is based on Fulgent Genetics' financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Fulgent Genetics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Fulgent Genetics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Fulgent Genetics helps investors to forecast how Fulgent stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Fulgent Genetics more accurately as focusing exclusively on Fulgent Genetics' fundamentals will not take into account other important factors: Traditionally analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Fulgent Genetics' intrinsic value based on its ongoing forecasts of Fulgent Genetics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Fulgent Genetics' closest peers. When choosing an evaluation method for Fulgent Genetics, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using both methods to arrive at a better estimate.
Fulgent Genetics Investments |
|
Fulgent Valuation Trend
Knowing Fulgent Genetics' actual value is paramount for traders to make sound investment determinations. Fulgent Genetics' real value is not only important for the investor to make better decisions but also for a more accurate overall view of Fulgent Genetics' financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both Fulgent Genetics' enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.
Fulgent Valuation Data Drivers
Fulgent valuation ratios help to determine how cheap or expensive it is, compared to its peers or based on some benchmark measure of value for a given date. A typical valuation ratio shows the difference between the cost of Fulgent equity instrument and the benefits of owning shares of Fulgent Genetics.
View More FundamentalsFulgent Market Cap
Fulgent Genetics is rated below average in market capitalization category among related companies. Market capitalization of Health Care industry is currently estimated at about 454.03 Billion. Fulgent Genetics adds roughly 619.54 Million in market capitalization claiming only tiny portion of equities under Health Care industry.Fulgent Genetics Valuation Ratios as Compared to Competition
Comparative valuation techniques use various fundamental indicators to help in determining Fulgent Genetics's current stock value. Our valuation model uses many indicators to compare Fulgent Genetics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Fulgent Genetics competition to find correlations between indicators driving Fulgent Genetics's intrinsic value. More Info.Fulgent Genetics is rated below average in price to earning category among related companies. It is rated below average in price to book category among related companies fabricating about 0.14 of Price To Book per Price To Earning. The ratio of Price To Earning to Price To Book for Fulgent Genetics is roughly 7.21 . Price To Book Ratio is likely to drop to 0.72 in 2024. Comparative valuation analysis is a catch-all model that can be used if you cannot value Fulgent Genetics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Fulgent Genetics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Fulgent Genetics' earnings, one of the primary drivers of an investment's value.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Fulgent Genetics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Fulgent Genetics and how it compares across the competition.
About Fulgent Genetics Valuation
The stock valuation mechanism determines the current worth of Fulgent Genetics on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Fulgent Genetics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Fulgent Genetics based exclusively on its fundamental and basic technical indicators. By analyzing Fulgent Genetics's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Fulgent Genetics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Fulgent Genetics. We calculate exposure to Fulgent Genetics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Fulgent Genetics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 96.6 M | 179.1 M | |
| Pretax Profit Margin | (0.60) | (0.57) | |
| Operating Profit Margin | (0.26) | (0.25) | |
| Net Loss | (0.58) | (0.61) | |
| Gross Profit Margin | 0.33 | 0.44 |
8 Steps to conduct Fulgent Genetics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Fulgent Genetics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Fulgent Genetics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Fulgent Genetics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Fulgent Genetics' revenue streams: Identify Fulgent Genetics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Fulgent Genetics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Fulgent Genetics' growth potential: Evaluate Fulgent Genetics' management, business model, and growth potential.
- Determine Fulgent Genetics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Fulgent Genetics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Fulgent Genetics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Fulgent Genetics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 29.8 M | |
| Quarterly Earnings Growth Y O Y | -0.986 | |
| Forward Price Earnings | 7.9365 |
Fulgent Genetics Current Valuation Indicators
Valuation refers to the process of determining the present value of Fulgent Genetics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Fulgent we look at many different elements of the entity such as Fulgent's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. Fulgent Genetics' valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Fulgent Genetics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Fulgent Genetics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Fulgent Genetics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Fulgent Genetics' worth.When determining whether Fulgent Genetics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Fulgent Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Fulgent Genetics Stock. Highlighted below are key reports to facilitate an investment decision about Fulgent Genetics Stock: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulgent Genetics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.Note that the Fulgent Genetics information on this page should be used as a complementary analysis to other Fulgent Genetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Complementary Tools for Fulgent Stock analysis
When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |
Is Fulgent Genetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulgent Genetics. If investors know Fulgent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulgent Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share (5.63) | Revenue Per Share 9.71 | Quarterly Revenue Growth 0.041 | Return On Assets (0.03) |
The market value of Fulgent Genetics is measured differently than its book value, which is the value of Fulgent that is recorded on the company's balance sheet. Investors also form their own opinion of Fulgent Genetics' value that differs from its market value or its book value, called intrinsic value, which is Fulgent Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulgent Genetics' market value can be influenced by many factors that don't directly affect Fulgent Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulgent Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulgent Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulgent Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.